Uveitis treatment shows promise

Article

Curcumin-based treatment Norflo, has been shown to alleviate the symptoms of anterior uveitis in a recent study published in Clinical Ophthalmology, indicating a potential role for the anti-inflammatory treatment curcumin in eye inflammatory and degenerative conditions.

Curcumin-based treatment Norflo, has been shown to alleviate the symptoms of anterior uveitis in a recent study published in Clinical Ophthalmology, indicating a potential role for the anti-inflammatory treatment curcumin in eye inflammatory and degenerative conditions.

The study conducted by Dr Pia Allegri et al., examined the efficacy of an adjunctive-to-traditional treatment with Norflo tablets (curcumin-phosphatidylcholine complex; Meriva) in recurrent anterior uveitis of different aetiologies.

Norflo, administered twice daily, was found to be well-tolerated, reducing the symptoms of anterior uveitis of different origins in more than 80% of the 106 patients treated. Thus the study indicated that the treatment can play an important role in the adjunctive therapy of recurrent anterior uveitis of various origins.

For further details please click here

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.